WO2015002378A1 - 멀꿀 잎 추출물을 유효성분으로 포함하는 골조직 생성 촉진용 약학 조성물 - Google Patents
멀꿀 잎 추출물을 유효성분으로 포함하는 골조직 생성 촉진용 약학 조성물 Download PDFInfo
- Publication number
- WO2015002378A1 WO2015002378A1 PCT/KR2014/003742 KR2014003742W WO2015002378A1 WO 2015002378 A1 WO2015002378 A1 WO 2015002378A1 KR 2014003742 W KR2014003742 W KR 2014003742W WO 2015002378 A1 WO2015002378 A1 WO 2015002378A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- pharmaceutical composition
- honey
- bone
- honey leaf
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 49
- 230000001737 promoting effect Effects 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 240000001490 Stauntonia hexaphylla Species 0.000 title abstract description 5
- 235000014570 Stauntonia hexaphylla Nutrition 0.000 title abstract description 5
- 230000009772 tissue formation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 14
- 201000001245 periodontitis Diseases 0.000 claims abstract description 14
- 235000012907 honey Nutrition 0.000 claims description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 210000000845 cartilage Anatomy 0.000 claims description 18
- 239000000287 crude extract Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 transdermal Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- 229940102223 injectable solution Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 65
- 230000004072 osteoblast differentiation Effects 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 210000003321 cartilage cell Anatomy 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 40
- 210000000963 osteoblast Anatomy 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 24
- 239000002038 ethyl acetate fraction Substances 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000921 morphogenic effect Effects 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000020083 shōchū Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Definitions
- the present invention relates to a pharmaceutical composition for promoting bone tissue production, and more specifically, to use for the purpose of inhibiting and treating bone and cartilage tissue damage that can be safely used without toxicity and side effects using natural ingredients containing honey leaf extract. It relates to a pharmaceutical composition for promoting bone tissue production.
- Bone tissue is generally made of dense bone with a strong surface of the bone, the center or both ends of the long bone ( ⁇ ⁇ ) is a bone of the corpus spongy bone ( ⁇ ⁇ ) associated with the bone. Most bones initially develop as cartilage in connective tissue, which later turns into bone tissue, some of which are made directly from connective tissue.
- the joint surface is in contact with the neighboring bone, and the surface is covered with the articular cartilage, which is a natural bone.
- Sea sponge shochu in the sponge is characterized by a certain arrangement. The wide course of the bony stem is continuous with the small lumen of sponge shochu and all are filled with bone marrow.
- Hematopoietic bone marrow has a lot of blood vessels distributed in red color, called red bone marrow.
- red bone marrow In the structure of bone, dense and spongy bones are overlapped with corrugated plates with a thickness of 5 to 12 ⁇ m. In dense material, several layers of concentric layers (harbor layer) are arranged in various directions. There is a harbor tube and blood vessels go through.
- Bone cells are arranged between the bone lamina plates and are connected to other bone cells adjacent to each other by a protoplasma that leads to an irregular star shape.
- a protoplasma On the surface of the bone is a tough connective tissue periosteum, and nerves and blood vessels are distributed to protect and nourish bone. Defects of the periosteum make it difficult to survive, develop, and regenerate bones.
- the bone components are 20% moisture, 35% organic matter including cells, 45% minerals, because the constant elasticity of bone is organic. As age increases, minerals (mainly calcium phosphate) increase and bone hardness also increases.
- the honey is Stauntonia hexaphylla , which belongs to the plant family, genus plant door, dicotyledonous plant, and buttercup. It is mainly distributed in Korea, Japan, Taiwan, China, etc., its main stem extends about 5m, leaves are alternate, and it is a palm-shaped double leaf with 5-7 small leaves. Small leaves are thick, egg-shaped or oval with flat edges. Petioles are 6-8cm long, petioles 3cm long. Flowers blossom in May, monogamous ( ⁇ ⁇ ), yellow-white, and hang on inflorescences.
- the small flower branch of the female flower is reddish brown in autumn, and there are many trees.
- Fruits are berry, egg-shaped or oval, 5 ⁇ 10cm long, ripened in reddish brown in October, and fruit flesh tastes better than um. Seeds are oval-shaped oval black.
- the present invention is a natural material commonly available in our country by using honey leaf extract to extract the ethyl acetate fraction of the honey leaf hydrothermal extract, honey leaf hydrothermal extract for the purpose of providing a pharmaceutical composition for the treatment and prevention of periodontitis or osteoporosis.
- Cell ALP activity and osteoblast differentiation promoting experiment and bone or cartilage tissue promoting experiment were conducted.
- Korean Laid-Open Patent Publication No. 10-2013-0020095 relates to a liver protective composition comprising a honey extract, and plant-derived honey extract for food has no side effects or safety problems, and carbon tetrachloride or acetanimophen (APAP), a liver toxic substance.
- APAP carbon tetrachloride or acetanimophen
- the composition discloses a pharmaceutical composition for treating or preventing liver disease or a food composition for improving liver function or protecting liver, as well as a composition that can be applied to various uses related to fatigue or hangover relief.
- Korean Patent Publication No. 10-11675890 relates to an anti-inflammatory composition
- an anti-inflammatory composition comprising honey fruit extract as an active ingredient.
- the honey fruit extract is not only cytotoxic, but also confirmed the level of transcription and NO secretion of various cytokines (cytokine) mRNA associated with inflammation, the honey fruit of the various parts of the honey to inhibit inflammation most effectively
- the anti-inflammatory composition comprising the same as an active ingredient has been disclosed with respect to an anti-inflammatory agent comprising a honey fruit extract, which can be applied as an anti-inflammatory and anti-inflammatory cosmetic composition having an anti-inflammatory effect in inflammation-related diseases.
- Korean Patent Publication No. 10-1243115 discloses an antipyretic agent comprising a honey leaf extract as an active ingredient, which is not only cytotoxic but also has an excellent antipyretic effect compared to existing antipyretic agents. have.
- Korean Patent Publication No. 10-1221617 relates to an anti-inflammatory composition
- honey leaf extract as an active ingredient.
- the honey leaf extract has not only cytotoxicity but also transcription level of cytokine (cytokine) mRNA related to inflammation.
- an anti-inflammatory agent comprising a honey leaf extract that can effectively inhibit inflammation by confirming the inhibitory activity of the secretion amount and COX-2 enzyme that causes inflammation.
- the honey extract is honey leaf hydrothermal extract, ethyl acetate fraction of the honey leaf hydrothermal extract for the purpose of utilizing the honey leaf extract as a natural material as in the present invention as a pharmaceutical composition for treating or preventing periodontitis or osteoporosis.
- the composition used as a composition for promoting osteoblast production by extracting osteoblast ALP activity and osteoblast differentiation promoting experiment and promoting the production of bone or cartilage tissue is different from the present invention in that it is not disclosed.
- the present invention by using a natural honey extract derived from the honey leaf as an active ingredient, a honeycomb extract containing a pharmaceutical composition for promoting bone tissue production that can be used for the inhibition and treatment of bone and cartilage tissue damage that is safe even without prolonged side effects.
- the present invention provides a pharmaceutical composition for promoting bone tissue production for the inhibition and treatment of bone and cartilage tissue damage, including a honey leaf crude extract or a non-polar soluble extract as an active ingredient.
- the honey leaf crude extract is an extract available in any one of water, methanol, ethanol, propanol, isopropanol, butanol, or a mixed solvent thereof.
- the nonpolar solvent may be any one selected from hexane, chloroform, dichloromethane and ethyl acetate. have.
- the honey leaf hot water extract has the function of increasing ALP activity and osteoblast differentiation produced in osteoblasts, and the ethyl acetate fraction of the honey leaf hot water extract has the function of increasing ALP activity and osteoblast differentiation produced in osteoblasts.
- the honey leaf extract is included as 0.01 to 99.9% by weight of the total pharmaceutical composition
- the daily dosage of the pharmaceutical composition is characterized in that the extract is provided in 10 to 1000mg / kg body weight.
- the ethyl acetate fraction of the honey leaf hydrothermal extract, the honey leaf extract as an active ingredient may be used as a treatment for periodontitis or osteoporosis for treating or preventing periodontitis or osteoporosis.
- 1 is a schematic diagram of the production of honey leaf hydrothermal extract and fractions
- Figure 2 is a graph showing the effect on the ALP activity of the honey leaf hydrothermal extract (osteoblast-promoting activity through osteoblast differentiation).
- Figure 3 is a graph showing the effect of honey leaf hydrothermal extract ethyl acetate fraction on the ALP activity.
- FIG. 4 is a graph showing the results of ALP activity staining of ethyl acetate fraction of honey leaf hydrothermal extract, honey leaf hydrothermal extract.
- the present invention provides a pharmaceutical composition for promoting bone tissue production for inhibiting and treating bone and cartilage tissue damage, including crude honey leaf extract or non-polar soluble extract as an active ingredient, and treatment for periodontitis or osteoporosis using the same.
- Figure 1 shows a schematic diagram for the production of honey leaf hydrothermal extract and fractions.
- 10 kg of leaves of Stauntonia hexaphylla were washed with distilled water, 200 L of distilled water was added thereto, and extracted by heating at 110 ° C. for 4 hours with an electric bath.
- the filtrate was filtered through a 400 mesh filter cloth and concentrated under reduced pressure. After filtration, the residue was extracted, filtered and concentrated under reduced pressure two more times using the same amount of distilled water.
- the concentrated hot water extract was freeze-dried in a freeze dryer. Through this process, 1 kg (10%) of honey leaf hydrothermal extract was obtained.
- honey leaf hot water extract prepared as shown in FIG. 1 was fractionated as follows using an organic solvent.
- Figure 2 is a graph showing the effect on the ALP activity of honey leaf hydrothermal extract (osteoblastic activity through osteoblast differentiation).
- osteoblasts exhibit ALP activity
- the effect of the honey leaf hydrothermal extract obtained on the ALP activity in osteoblasts was measured.
- C2C12 cells, osteoblasts were dispensed to 48 x 5 wells at 5 x 10 ⁇ 4 cells / well and cells were cultured for 3 days in ⁇ -MEM essential medium containing 10% FBS and 0.1% p / s of cell growth medium. Incubated. After 3 days, the cells were exchanged with ⁇ -MEM essential medium containing 1% horse serum and 0.1% p / s to induce osteoblast differentiation.
- BMP-2 bone morphogenic protein-2
- ALP activity was measured using a change in absorbance at 405 nm using ALP to decompose p-nitrophenylphosphate into p-nitrophenol and phosphate. Protein concentration was determined using the BioRad protein assay kit. ALP activity was expressed as PNP uM / min / mg protein.
- honey leaf hydrothermal extracts obtained through the process of extracting the honey leaf hydrothermal and obtaining the fractions were treated to the osteoblasts (C2C12 cel) l by concentration, that is, the hydrothermal extract (10, 50ug / ml), and then cultured for 4 days.
- the effect on ALP activity was measured and the results are shown graphically in FIG. 2.
- FIG. 2 As shown in Figure 2, in the experimental group treated with BMP-2 and honey leaf hot water extract (10, 50ug / ml) at the same time, it was observed that the ALP activity increased in a concentration-dependent manner compared to the control group treated with BMP-2 .
- Figure 3 is a graph showing the effect of honey leaf hydrothermal extract ethyl acetate fraction on the ALP activity.
- osteoblasts exhibited ALP activity
- the effect of the ethyl acetate fraction of the honey leaf hydrothermal extract obtained on osteoblasts in the osteoblasts was measured. Specifically, C2C12 cells, osteoblasts, were divided into 48 wells at 5 x 10 ⁇ 4 cells / well and cells were cultured for 3 days in ⁇ -MEM essential medium containing 10% FBS and 0.1% p / s of cell growth medium. Incubated.
- the cells were exchanged with ⁇ -MEM essential medium containing 1% horse serum and 0.1% p / s to induce osteoblast differentiation. Thereafter, 10ng / ml of BMP-2 (bone morphogenic protein-2) was treated, and HP-20 column eluate HP20-2 of butanol fraction of honey leaf hydrothermal extract was treated simultaneously by concentration (5, 10ug / ml). After 4 days incubation. Subsequently, the cells were treated with AP assay buffer (kit) containing 0.01% Triton X, followed by centrifugation at 1000 x g for 5 minutes to obtain a sample for ALP activity detection.
- kit AP assay buffer
- ALP activity was measured using a change in absorbance at 405 nm using ALP to decompose p-nitrophenylphosphate into p-nitrophenol and phosphate. Protein concentration was determined using the BioRad protein assay kit. ALP activity was expressed as PNP uM / min / mg protein.
- Ethyl acetate fractions of the honey leaf hydrothermal extracts were treated with different concentrations, that is, ethyl acetate fractions (5, 10 ug / ml) of the honey leaf hydrothermal extracts were treated with osteoblasts (C2C12 cells), and cultured for 4 days, followed by ALP activity of osteoblasts. The effect on the measurement was measured and the results are shown graphically in FIG.
- ALP is an enzyme released by differentiation and activity of osteoblasts. Since the increase of ALP activity is directly related to osteoblast activity and increase, the increase of ALP activity by ethyl acetate of the honey leaf hydrothermal extract of the present invention It is to demonstrate the effect of promoting osteoblast formation by direct osteoblast differentiation and increased activity.
- C2C12 cells, osteoblasts were dispensed into 48 wells at 5 x 104 cells / well and cultured for 3 days in ⁇ -MEM essential medium containing 10% FBS and 0.1% p / s of cell growth medium. After 3 days, the cells were exchanged with ⁇ -MEM essential medium containing 1% horse serum and 0.1% p / s to induce osteoblast differentiation. Thereafter, 10ng / ml of BMP-2 (bone morphogenic protein-2) was treated, and the samples were simultaneously treated for each concentration, followed by incubation for 4 days.
- BMP-2 bone morphogenic protein-2
- the culture solution of the cells after 4 days of incubation is removed and the cells are washed 3 times with 1xPBS. Fix the cells for 15 minutes at room temperature with 10% formalin solution and wash the cells 3 times with 1xPBS to remove residual formalin. The cells were washed again with 1 ⁇ alkaline phosphaste solution and then stained with AP active sites with NBT / BCIP substrate solution.
- FIG. 4 is a graph showing the results of ALP activity staining of ethyl acetate fraction of honey leaf hydrothermal extract, honey leaf hydrothermal extract. As shown in Figure 4, the experimental results of the positive control group treated only with BMP-2, it was confirmed that the cell staining by NBT / BCIP more than the normal group not treated with BMP-2 and the sample.
- ALP is an enzyme released by osteoblast differentiation and increased activity. Since the increase of ALP activity is directly related to osteoblast activity and increase, the ALP activity by ethyl acetate fraction of the honey leaf hydrothermal extract of the present invention is increased. It can be said that the direct osteoblast differentiation and activation by the bone formation promoting effect.
- a pharmaceutical composition for promoting the production of bone and cartilage tissue comprising crude honey leaf extract as an active ingredient and a treatment for preventing periodontitis or osteoporosis
- Periodontitis, osteoporosis prevention or treatment using the pharmaceutical composition for promoting bone or cartilage tissue production powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, transdermals, suppositories so that the composition is contained in 0.01 to 99.9% by weight Or in the form of sterile injectable solutions.
- the pharmaceutical composition may be contained in an amount of 0.01 to 99.9% by weight, and 99.9 to 0.01% by weight of purified water or glucose may be mixed.
- the pharmaceutical composition may be freeze-dried to include 0.01 to 99.9% by weight, and vitamins and calcium may be prepared by mixing 99.9 to 0.01% by weight.
- Daily dosage of the prepared pharmaceutical composition is provided in an amount of 10 to 1000mg / kg body weight of the extract.
- the pharmaceutical composition may be prepared as a functional health food for periodontitis or osteoporosis improvement, prevention comprising 0.01 to 99.9% by weight.
- the ethyl acetate fraction of the honey leaf hydrothermal extract, the honey leaf extract as an active ingredient may be used as a treatment for periodontitis or osteoporosis for treating or preventing periodontitis or osteoporosis, and by replacing the raw material with plants inhabiting nature, it may be expected to reduce the production cost and import substitution and export effect through industrialization.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
- 멀꿀 잎 조추출물을 유효성분으로 포함하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제1항에 있어서, 상기 멀꿀 잎 조추출물은 물, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 또는 이들의 혼합용매 중에서 선택되는 어느 하나로부터 가용한 추출물인 것을 특징으로 하는 멀꿀 잎 조추출물을 함유하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제2항에 있어서, 상기 용매를 사용하여 추출한 황칠 잎 조추출물에 비극성용매로서 헥산, 클로로포름, 디클로메탄 및 에틸아세테이트 중에서 선택되는 어느 하나를 분획용매로 사용하여 분획한 것을 특징으로 하는 멀꿀 잎 조추출물을 함유하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제1항 내지 제3항 중 어느 한 항의 조성물은 0.01 내지 99.9중량%로 포함되는 것을 특징으로 하는 멀꿀 잎 조추출물을 함유하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제4항에 있어서, 상기 추출물의 1일당 투여량은 체중 kg당 10 내지 1000mg/kg의 양으로 공급되는 것을 특징으로 하는 멀꿀 잎 조추출물을 포함하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제4항 또는 제5항에 있어서, 상기 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸, 경피제, 좌제 또는 멸균 주사용 액으로 제형화된 것을 특징으로 하는 멀꿀 잎 조추출물을 포함하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제1항 내지 제6항 중 어느 한 항에 있어서 상기 추출물은 치주염, 골다공증 예방 또는 치료용으로 사용되는 것을 특징으로 하는 멀꿀 잎 조추출물을 포함하는 골 또는 연골조직 생성 촉진용 약학 조성물
- 제1항 내지 제3항 중 어느 한 항의 골 또는 연골조직 생성 촉진용 약학 조성물을 0.01 내지 99.9중량%로 포함하는 치주염 또는 골다공증 개선, 예방용 기능성 건강식품
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES14819974T ES2767351T3 (es) | 2013-06-30 | 2014-04-29 | Composición farmacéutica para promover la formación de tejido óseo, que contiene el extracto de hoja de Stauntonia hexaphylla como ingrediente activo |
CN201480026859.8A CN105407903B (zh) | 2013-06-30 | 2014-04-29 | 含有五指那藤叶提取物作为有效成分的骨组织生成促进用药物组合物 |
US14/889,006 US10328110B2 (en) | 2013-06-30 | 2014-04-29 | Pharmaceutical composition for promoting bone tissue formation, containing Stauntonia hexaphylla leaf extract as active ingredient |
AU2014284932A AU2014284932B2 (en) | 2013-06-30 | 2014-04-29 | Pharmaceutical composition for promoting bone tissue formation, containing Stauntonia hexaphylla leaf extract as active ingredient |
CA2911745A CA2911745C (en) | 2013-06-30 | 2014-04-29 | Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient |
PL14819974T PL3031465T3 (pl) | 2013-06-30 | 2014-04-29 | Kompozycja farmaceutyczna do sprzyjania tworzeniu tkanki kostnej, zawierająca jako składnik czynny wyciąg z liści stauntonia hexaphylla |
JP2016512820A JP6104462B2 (ja) | 2013-06-30 | 2014-04-29 | ムベ葉抽出物を有効成分として含む骨組織生成促進用薬学組成物 |
EP14819974.8A EP3031465B1 (en) | 2013-06-30 | 2014-04-29 | Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0076190 | 2013-06-30 | ||
KR1020130076190A KR101532832B1 (ko) | 2013-06-30 | 2013-06-30 | 멀꿀 잎 추출물을 유효성분으로 포함하는 골조직 생성 촉진용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015002378A1 true WO2015002378A1 (ko) | 2015-01-08 |
Family
ID=52143929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/003742 WO2015002378A1 (ko) | 2013-06-30 | 2014-04-29 | 멀꿀 잎 추출물을 유효성분으로 포함하는 골조직 생성 촉진용 약학 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10328110B2 (ko) |
EP (1) | EP3031465B1 (ko) |
JP (1) | JP6104462B2 (ko) |
KR (1) | KR101532832B1 (ko) |
CN (2) | CN105407903B (ko) |
AU (1) | AU2014284932B2 (ko) |
CA (1) | CA2911745C (ko) |
ES (1) | ES2767351T3 (ko) |
PL (1) | PL3031465T3 (ko) |
WO (1) | WO2015002378A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102038108B1 (ko) * | 2016-12-29 | 2019-10-29 | 영진약품 주식회사 | 멀꿀 잎 추출물로부터 분리된 신규한 카페인산 화합물 및 이를 유효성분으로 하는 항염, 골조직 생성 또는 연골조직 생성 촉진용 조성물 |
KR102038107B1 (ko) * | 2016-12-29 | 2019-10-29 | 영진약품 주식회사 | 멀꿀 잎 추출물로부터 분리된 신규한 플라보노이드 화합물 및 이를 유효성분으로 하는 항염, 골조직 생성 또는 연골조직 생성 촉진용 조성물 |
CN107259256B (zh) * | 2017-07-18 | 2020-12-29 | 福建农林大学 | 一种五指那藤功能饮品及其制备方法 |
KR102126575B1 (ko) * | 2017-11-03 | 2020-06-24 | 영진약품 주식회사 | 멀꿀 잎 유래 추출물 또는 분획 정제물 또는 이로부터 분리된 신규 플라보노이드 화합물 및 카페인산 화합물을 유효성분으로 포함하는 항염, 또는 골조직 생성 또는 연골조직 생성 촉진용 약학적 조성물 |
KR102241369B1 (ko) * | 2020-02-25 | 2021-04-15 | 영진약품 주식회사 | 멀꿀 잎 유래 추출물 또는 분획 정제물 또는 이로부터 분리된 신규 플라보노이드 화합물 및 카페인산 화합물을 유효성분으로 포함하는 항염, 또는 골조직 생성 또는 연골조직 생성 촉진용 약학적 조성물 |
KR102625435B1 (ko) * | 2023-03-17 | 2024-01-18 | (주)제이비 바이오 | 천연발효효소복합액을 이용한 멀꿀 발효물과 이를 이용한 골밀도 개선, 뼈 성장촉진, 키 성장촉진 또는 관절건강증진용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101167589B1 (ko) | 2011-08-18 | 2012-07-27 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 열매 추출물을 포함하는 항염증제 |
KR101221617B1 (ko) | 2012-04-16 | 2013-01-14 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 잎 추출물을 포함하는 항염증제 |
KR20130020095A (ko) | 2011-08-18 | 2013-02-27 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 추출물을 포함하는 간 보호용 조성물 |
KR101243115B1 (ko) | 2012-04-17 | 2013-03-12 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 잎 추출물을 포함하는 해열제 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100497945B1 (ko) * | 2001-06-26 | 2005-06-29 | 한국 한의학 연구원 | 성장호르몬 분비촉진용 생약추출물 |
JP2011195532A (ja) * | 2010-03-23 | 2011-10-06 | Shiseido Co Ltd | タンパク質糖化抑制剤 |
JP2011201811A (ja) * | 2010-03-25 | 2011-10-13 | Shiseido Co Ltd | Tie2活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
EP2692352A4 (en) * | 2011-03-31 | 2014-12-24 | Shiseido Co Ltd | MEANS FOR SUPPRESSING HEADWALLS |
US9370542B2 (en) * | 2011-08-18 | 2016-06-21 | Jeonnam Bioindustry Foundation | Medical composition containing Stauntonia hexaphylla extract |
KR101317668B1 (ko) * | 2012-09-03 | 2013-10-15 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 잎 추출물을 유효성분으로 포함하는 관절염 치료 또는 예방용 약학 조성물 |
-
2013
- 2013-06-30 KR KR1020130076190A patent/KR101532832B1/ko active IP Right Grant
-
2014
- 2014-04-29 CN CN201480026859.8A patent/CN105407903B/zh active Active
- 2014-04-29 CN CN202010078823.1A patent/CN111494474A/zh active Pending
- 2014-04-29 JP JP2016512820A patent/JP6104462B2/ja active Active
- 2014-04-29 PL PL14819974T patent/PL3031465T3/pl unknown
- 2014-04-29 US US14/889,006 patent/US10328110B2/en active Active
- 2014-04-29 ES ES14819974T patent/ES2767351T3/es active Active
- 2014-04-29 WO PCT/KR2014/003742 patent/WO2015002378A1/ko active Application Filing
- 2014-04-29 AU AU2014284932A patent/AU2014284932B2/en active Active
- 2014-04-29 EP EP14819974.8A patent/EP3031465B1/en active Active
- 2014-04-29 CA CA2911745A patent/CA2911745C/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101167589B1 (ko) | 2011-08-18 | 2012-07-27 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 열매 추출물을 포함하는 항염증제 |
KR20130020095A (ko) | 2011-08-18 | 2013-02-27 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 추출물을 포함하는 간 보호용 조성물 |
KR101221617B1 (ko) | 2012-04-16 | 2013-01-14 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 잎 추출물을 포함하는 항염증제 |
KR101243115B1 (ko) | 2012-04-17 | 2013-03-12 | 재단법인 전라남도생물산업진흥재단 | 멀꿀 잎 추출물을 포함하는 해열제 |
Non-Patent Citations (2)
Title |
---|
HUAI-BIN WANG ET AL.: "TRITERPENOID GLYCOSIDES FROM STAUNTONIA HEXAPHYLLA", PHYTOCHEMISTRY, vol. 34, no. 5, 1 November 1993 (1993-11-01), pages 1389 - 1394, XP026631130 * |
HUAI-BIN WANG: "BISEPOXYLIGNAN GLYCOSIDES FROM STAUNTONIA HEXAPHYLLA", PHYTOCHEMISTRY, vol. 34, no. 6, 1 December 1993 (1993-12-01), pages 1621 - 1624, XP026631691 * |
Also Published As
Publication number | Publication date |
---|---|
CA2911745C (en) | 2019-08-06 |
US10328110B2 (en) | 2019-06-25 |
AU2014284932A1 (en) | 2015-11-26 |
KR101532832B1 (ko) | 2015-06-30 |
JP2016520059A (ja) | 2016-07-11 |
US20160113979A1 (en) | 2016-04-28 |
EP3031465A1 (en) | 2016-06-15 |
EP3031465B1 (en) | 2019-11-13 |
AU2014284932B2 (en) | 2017-09-14 |
CN105407903A (zh) | 2016-03-16 |
CN105407903B (zh) | 2020-08-07 |
CA2911745A1 (en) | 2015-01-08 |
PL3031465T3 (pl) | 2020-05-18 |
JP6104462B2 (ja) | 2017-03-29 |
ES2767351T3 (es) | 2020-06-17 |
EP3031465A4 (en) | 2017-03-01 |
CN111494474A (zh) | 2020-08-07 |
KR20150002398A (ko) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015002378A1 (ko) | 멀꿀 잎 추출물을 유효성분으로 포함하는 골조직 생성 촉진용 약학 조성물 | |
WO2019083321A2 (ko) | 항산화, 항염 또는 파골세포 분화 억제용 조성물 | |
WO2018101630A1 (ko) | 모새나무 열매 추출물을 포함하는 우울증 예방 및 개선용 건강기능성 식품조성물 | |
KR101192409B1 (ko) | 낙석등 건조 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약제학적 조성물과 상기 분획물의 제조방법 | |
WO2019083168A1 (ko) | 호장근과 계심을 함유하는 항혈전용 조성물 | |
WO2016080691A1 (ko) | 노린재나무 및 황기의 추출물을 포함하는 관절염의 예방 또는 치료용 약학 조성물 및 그 제조방법 | |
WO2018111042A2 (ko) | 한약재 추출물을 유효성분으로 포함하는 화장료 조성물 | |
WO2014119875A1 (ko) | 황칠 잎 열수 추출물을 함유하는 진해 또는 거담용 약학 조성물 | |
WO2014025202A1 (ko) | 작약, 건강 혼합추출물을 포함하는 치매 및 인지기능장애 예방 또는 치료용 약제학적 조성물 | |
WO2022035078A1 (ko) | 신혈관생성 및 세포재생 효과를 갖는 해조류 유래 폴리데옥시리보뉴클레오타이드 및 폴리뉴클레오타이드 및 추출방법 | |
WO2024005561A1 (ko) | 노각나무 추출물을 유효성분으로 포함하는 치매의 예방 또는 치료용 조성물 | |
WO2011108907A2 (ko) | 한방추출물을 유효성분으로 함유하는 소양증 및 아토피 개선용 조성물 | |
KR101420135B1 (ko) | 학습 장애, 기억력 장애 또는 치매의 예방 또는 치료용 두충 추출물 | |
WO2018080157A1 (ko) | 천선과나무 추출물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2021045569A1 (ko) | 빌베리 추출물을 유효성분으로 함유하는 감각신경성 난청 예방 또는 치료용 조성물 | |
KR20160008131A (ko) | 멀꿀 잎 조추출물을 유효성분으로 포함하는 조골 또는 연골조직 생성 촉진용 기능성 식품조성물 | |
WO2016178490A2 (ko) | 곰보배추 추출물 또는 이의 분획물을 포함하는 통풍 예방 또는 치료용 약학적 조성물 및 고요산혈증 개선용 식품 조성물 | |
KR101385191B1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 | |
KR20150021096A (ko) | 멀꿀 잎 조추출물을 유효성분으로 포함하는 연골조직 생성 촉진용 약학 조성물 | |
WO2010005256A2 (ko) | 산사나무의 열매 또는 씨앗으로부터 얻어진 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
WO2015093634A1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 | |
WO2014182004A1 (ko) | 까마귀쪽나무의 오일을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 조성물과 이의 제조방법 | |
WO2024096280A1 (ko) | 포도나무 줄기 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 알츠하이머 예방, 개선 또는 치료용 조성물 | |
WO2010036065A9 (ko) | 낙석등 건조 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약제학적 조성물과 상기 분획물의 제조방법 | |
WO2017022964A1 (ko) | 멀꿀 열매 추출물을 유효성분으로 포함하는 알콜성 간 손상에 대한 간 보호 기능을 갖는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480026859.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14819974 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014819974 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2911745 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14889006 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016512820 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014284932 Country of ref document: AU Date of ref document: 20140429 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |